AA
LFCR icon

Ancora Advisors’s Lifecore Biomedical LFCR Stock Holding History

Ancora Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-77,551
Closed -$502K – 2013
2022
Q4 		$502K Buy
77,551
+7,002
+10% +$57.7K 0.01% 484
2022
Q3 		$628K Hold
70,549
– – 0.02% 460
2022
Q2 		$703K Hold
70,549
– – 0.02% 451
2022
Q1 		$817K Hold
70,549
– – 0.02% 430
2021
Q4 		$783K Sell
70,549
-8,540
-11% -$82.9K 0.02% 439
2021
Q3 		$729K Hold
79,089
– – 0.02% 454
2021
Q2 		$890K Buy
79,089
+14,845
+23% +$171K 0.02% 422
2021
Q1 		$681K Hold
64,244
– – 0.02% 458
2020
Q4 		$697K Sell
64,244
-2,600
-4% -$26.9K 0.02% 415
2020
Q3 		$650K Sell
66,844
-3,632
-5% -$34.6K 0.03% 387
2020
Q2 		$561K Sell
70,476
-4,474
-6% -$46.2K 0.02% 405
2020
Q1 		$651K Sell
74,950
-19,823
-21% -$206K 0.03% 407
2019
Q4 		$1.07M Buy
94,773
+3,267
+4% +$34.8K 0.04% 353
2019
Q3 		$995K Buy
91,506
+582
+0.6% +$6.34K 0.04% 328
2019
Q2 		$852K Sell
90,924
-18,064
-17% -$182K 0.04% 319
2019
Q1 		$1.34M Sell
108,988
-700
-0.6% -$8.55K 0.06% 265
2018
Q4 		$1.3M Buy
109,688
+1,495
+1% +$20.5K 0.06% 255
2018
Q3 		$1.56M Buy
108,193
+633
+0.6% +$8.75K 0.06% 274
2018
Q2 		$1.6M Buy
107,560
+575
+0.5% +$7.99K 0.07% 257
2018
Q1 		$1.4M Buy
106,985
+3,390
+3% +$44.5K 0.06% 272
2017
Q4 		$1.3M Buy
103,595
+19,177
+23% +$242K 0.07% 260
2017
Q3 		$1.09M Buy
84,418
+4,605
+6% +$60.7K 0.06% 303
2017
Q2 		$1.19M Buy
79,813
+2,637
+3% +$36.7K 0.08% 277
2017
Q1 		$926K Hold
77,176
– – 0.06% 323
2016
Q4 		$1.06M Hold
77,176
– – 0.08% 277
2016
Q3 		$1.03M Hold
77,176
– – 0.1% 218
2016
Q2 		$830K Hold
77,176
– – 0.1% 229
2016
Q1 		$810K Hold
77,176
– – 0.1% 229
2015
Q4 		$913K Hold
77,176
– – 0.12% 202
2015
Q3 		$901K Hold
77,176
– – 0.12% 220
2015
Q2 		$1.11M Buy
+77,176
New +$1.11M 0.13% 202
2015
Q1 		– Sell
-80,676
Closed -$1.11M – 200
2014
Q4 		$1.11M Sell
80,676
-800
-1% -$10.3K 0.14% 195
2014
Q3 		$998K Hold
81,476
– – 0.13% 200
2014
Q2 		$1.02M Hold
81,476
– – 0.13% 195
2014
Q1 		$909K Hold
81,476
– – 0.13% 195
2013
Q4 		$987K Buy
81,476
+5,000
+7% +$59.7K 0.15% 173
2013
Q3 		$933K Buy
76,476
+10,000
+15% +$140K 0.16% 164
2013
Q2 		$878K Buy
+66,476
New +$919K 0.15% 168

Other funds holding LFCR

GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

Ancora Advisors's LFCR Position: Q1 2023 in Review

Ancora Advisors sold out of Lifecore Biomedical (LFCR) in Q1 2023, closing a stake of 77,551 shares — an estimated $502K sold.

Ancora Advisors first reported a position in LFCR in Q2 2013 and held it in 38 quarters. The position peaked at $1.6M in Q2 2018. 82 funds tracked by Wall St. Rank hold LFCR as of Q1 2023.

  • Ancora Advisors reported no remaining Lifecore Biomedical position as of Q1 2023 after selling out during the quarter.
  • Ancora Advisors sold 77,551 Lifecore Biomedical shares in Q1 2023, an estimated $502K.
  • Ancora Advisors first reported a position in Lifecore Biomedical in Q2 2013 and held it in 38 quarters.
  • Ancora Advisors's Lifecore Biomedical position peaked at $1.6M in Q2 2018.
  • 82 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2023.

Based on Ancora Advisors's 13F filing for Q1 2023, filed 16 May 2023.